% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schwarzlmueller:300120,
      author       = {P. Schwarzlmueller and A. Triebig and G. Assié and A.
                      Jouinot and S. Theurich$^*$ and T. Maier and F. Beuschlein
                      and S. Kobold$^*$ and M. Kroiss},
      title        = {{S}teroid hormones as modulators of anti-tumoural
                      immunity.},
      journal      = {Nature reviews / Endocrinology},
      volume       = {21},
      number       = {6},
      issn         = {1759-5029},
      address      = {London [u.a.]},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2025-00618},
      pages        = {331-343},
      year         = {2025},
      note         = {2025 Jun;21(6):331-343},
      abstract     = {Immune evasion is a hallmark of cancer progression but the
                      role of steroid hormones in this evasion has long been
                      underrated. This oversight is particularly notable for
                      glucocorticoids given that exogenous glucocorticoids remain
                      a cornerstone therapy in various oncological treatment
                      regimens, supportive care and treatment of immune-related
                      adverse events caused by immune-checkpoint inhibitors.
                      Cortisol, the main endogenous glucocorticoid in humans, is
                      secreted by the adrenal cortex in response to stress.
                      Additionally, cortisol and its inactive metabolite cortisone
                      can be interconverted to further modulate tissue-dependent
                      glucocorticoid action. In the past 5 years, intratumoural
                      production of glucocorticoids, by both immune and tumour
                      cells, has been shown to support tumour immune evasion.
                      Here, we summarize current progress at the crossroads of
                      endocrinology and immuno-oncology. We outline the known
                      effects of steroid hormones on different immune cell types
                      with a focus on glucocorticoids and androgens. We conclude
                      with options for pharmaceutical intervention, including the
                      engineering of cell-based therapies that resist the
                      immunosuppressive action of steroid hormones. Overall, local
                      steroid production and metabolism are emerging elements of
                      tumour immune suppression that are potentially amenable to
                      therapeutic intervention. Targeting steroid hormones to
                      enhance anticancer therapies could increase their efficacy
                      but will require expertise in endocrine care.},
      subtyp        = {Review Article},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40128599},
      doi          = {10.1038/s41574-025-01102-2},
      url          = {https://inrepo02.dkfz.de/record/300120},
}